"Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer
Cancer Drug Research Laboratory, Division of Medical Oncology, Department of Medicine, McGill University Health Center/Royal Victoria Hospital, Montreal, Quebec H3A 1A1, Canada.